According to Zacks, “CHF Solutions, Inc. is a medical device company which focused on commercializing the Aquadex FlexFlow (R) System. Its commercial product Aquadex system, is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. CHF Solutions Inc., formerly known as Sunshine Heart Inc., is headquartered in Minneapolis. “
Separately, ValuEngine upgraded shares of CHF Solutions from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.
CHF Solutions (NASDAQ:CHFS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($1.93) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.46) by ($0.47). The business had revenue of $1.68 million during the quarter. CHF Solutions had a negative return on equity of 188.38% and a negative net margin of 306.81%. Analysts expect that CHF Solutions will post -6.02 EPS for the current year.
An institutional investor recently bought a new position in CHF Solutions stock. Perkins Capital Management Inc. purchased a new stake in shares of CHF Solutions Inc (NASDAQ:CHFS) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 114,285 shares of the company’s stock, valued at approximately $470,000. Perkins Capital Management Inc. owned 17.32% of CHF Solutions as of its most recent SEC filing. 10.17% of the stock is currently owned by institutional investors.
CHF Solutions Company Profile
CHF Solutions, Inc, a medical device company, focuses on the provision of solutions for patients suffering from fluid overload. The company's commercial product is the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
See Also: Net Asset Value
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.